Regeneron Pharmaceuticals Inc. buy phonebroker
Start price
24.06.15
/
50%
€458.60
Target price
20.07.15
€490.00
Performance (%)
11.97%
End price
20.07.15
€513.50
Summary
This prediction ended on 20.07.15 with a price of €513.50. The BUY prediction by phonebroker finished with a performance of 11.97%. phonebroker has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 4.950% | 4.950% | 23.389% | -13.141% |
| iShares Core DAX® | 2.480% | 1.738% | 6.882% | 55.581% |
| iShares Nasdaq 100 | -0.982% | -2.736% | 33.971% | 86.280% |
| iShares Nikkei 225® | -4.893% | 1.345% | 57.015% | 72.651% |
| iShares S&P 500 | 1.062% | 0.054% | 25.183% | 65.844% |
Comments by phonebroker for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Spekulativ kaufen
Gute Nachrichtenlage, schöne Kursentwicklung.
(Vom Mitglied beendet)